Equity Profile

FOLD

Amicus Therapeutics, Inc.

Health CareBiotechnology$4.5B

May4Mon

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EDT

Company Snapshot

Amicus Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.08

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$160M

Wall Street expectations, options signals, track record, and call prep available with Pro.

FOLD Q1-2026 Earnings Preview

Context

Company Snapshot

Amicus Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare genetic diseases. With a market cap of $5 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+157.80%

Avg Stock Reaction

-1.80%

Last Quarter Recap

In the last quarter, Amicus reported an EPS of $0.10, significantly beating expectations. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Continued focus on advancing its pipeline of therapies.
Commitment to improving patient access to treatments.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic ahead of the earnings report, with expectations of a slight loss but steady revenue growth.

Bull Case

If Amicus can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products and a positive outlook.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides weak guidance, it could raise concerns about its growth prospects.

Key Metrics to Watch

EPS

$-0.08

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$160M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amicus achieve revenue of at least $160 million this quarter?

Meeting or exceeding this revenue target will be crucial for demonstrating strong market demand and growth potential.

How does management plan to address the recent fluctuations in EPS?

Investors will be keen to understand the company's strategy for improving profitability and managing costs.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Amicus to leverage its recent product advancements to drive revenue growth beyond the consensus.

Supporting Evidence

The company's recent history of beating EPS estimates suggests a stronger operational performance than anticipated.

Options pricing indicates a lower expected move compared to historical averages, suggesting the market may be overly cautious.

Management's commitment to improving patient access could lead to increased sales that are not fully reflected in current estimates.

Key Risk

If revenue exceeds $160 million, it could significantly shift market sentiment and validate the company's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Amicus can sustain its growth trajectory amid recent earnings surprises and fluctuating performance.

Bull Confirmed If

Achieving an EPS of $0.00 or better would confirm the bull case and indicate a turnaround in profitability.

Bear Confirmed If

An EPS loss greater than the consensus of $-0.08 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±5.5%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting uncertainty but not extreme volatility.

Options are pricing ±3.8% while FOLD has averaged ±5.5% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.7%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amicus beats expectations, history suggests a potential average move of +1.13% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a decline of around -6.51% on the following day, indicating disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected market launch dates.
2Details on patient access initiatives and their impact on sales.
3Management's outlook on competitive pressures in the biotechnology sector.
4Clarification on cost management strategies and their effect on profitability.
5Insights into market demand for existing products and any new developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Amicus Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.08

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$160M

Wall Street expectations, options signals, track record, and call prep available with Pro.

FOLD Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+157.80%

Avg Stock Reaction

-1.80%

Last Quarter Recap

In the last quarter, Amicus reported an EPS of $0.10, significantly beating expectations. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Continued focus on advancing its pipeline of therapies.
Commitment to improving patient access to treatments.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic ahead of the earnings report, with expectations of a slight loss but steady revenue growth.

Bull Case

If Amicus can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products and a positive outlook.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides weak guidance, it could raise concerns about its growth prospects.

Key Metrics to Watch

EPS

$-0.08

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$160M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amicus achieve revenue of at least $160 million this quarter?

Meeting or exceeding this revenue target will be crucial for demonstrating strong market demand and growth potential.

How does management plan to address the recent fluctuations in EPS?

Investors will be keen to understand the company's strategy for improving profitability and managing costs.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Amicus to leverage its recent product advancements to drive revenue growth beyond the consensus.

Supporting Evidence

The company's recent history of beating EPS estimates suggests a stronger operational performance than anticipated.

Options pricing indicates a lower expected move compared to historical averages, suggesting the market may be overly cautious.

Management's commitment to improving patient access could lead to increased sales that are not fully reflected in current estimates.

Key Risk

If revenue exceeds $160 million, it could significantly shift market sentiment and validate the company's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Amicus can sustain its growth trajectory amid recent earnings surprises and fluctuating performance.

Bull Confirmed If

Achieving an EPS of $0.00 or better would confirm the bull case and indicate a turnaround in profitability.

Bear Confirmed If

An EPS loss greater than the consensus of $-0.08 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±5.5%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting uncertainty but not extreme volatility.

Options are pricing ±3.8% while FOLD has averaged ±5.5% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.7%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amicus beats expectations, history suggests a potential average move of +1.13% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a decline of around -6.51% on the following day, indicating disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected market launch dates.
2Details on patient access initiatives and their impact on sales.
3Management's outlook on competitive pressures in the biotechnology sector.
4Clarification on cost management strategies and their effect on profitability.
5Insights into market demand for existing products and any new developments.